Belgium-based, clinical-stage, biotechnology company Galapagos has begun a Phase l trial of GLPG2451 potentiator to treat cystic fibrosis (CF).

CF is a genetic disorder that affects mostly the lungs and also the pancreas, liver, kidneys and intestine.

After GLPG1837, GLPG2451 is said to be the second potentiator compound in the comapny’s extended CF-portfolio to enter clinical trials.

As part of the trial, a randomised, double-blind, placebo-controlled study will be conducted over a range of doses of GLPG2451 in healthy volunteers within both Belgium and the Netherlands.

"Galapagos and AbbVie seek to develop a triple CFTR combination therapy to address 90% of patients with CF."

Results of the study are expected to come in the last quarter of this year.

The start of this Phase l trial has witnessed a $10m payment from US-based pharmaceutical company AbbVie under a recently expanded global collaboration agreement.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Galapagos and AbbVie seek to develop a triple CFTR combination therapy to address 90% of patients with CF.

In order to bring a more effective therapy to patients, the companies have also developed multiple candidates and backups for each of the three components of a potential triple combination.

GLPG2451 is the second potentiator and the third compound in the portfolio to enter the clinical stage of development.

For the potentiator series, Galapagos is recruiting for the SAPHIRA exploratory Phase ll programme with the first potentiator, GLPG1837, in patients with G551D and S1251N mutations.

Results from the SAPHIRA programme are expected in the second half of this year.

Galapagos noted that dosing to humans of GLPG2222, the first early binding corrector in Galapagos’ portfolio, started in January this year.

The company is currently conducting a randomised, double-blind, placebo-controlled study over a range of doses of GLPG2222 in healthy volunteers within Belgium and expects results in this year’s second quarter.

Earlier this year, Galapagos selected preclinical candidate GLPG2851, an additional early binding corrector.

The company selected the first late binding corrector GLPG2665 last year, along with an additional late binding corrector this year in the same series, GLPG2737.

Galapagos expects to enter Phase l with one of these late binding correctors in healthy volunteers during the second half of this year.